As the average life expectancy is prolonged, the number of elderly people is increasing. It is estimated that the prevalence of diabetes worldwide will increase to 642 million by 2040, and the highest age-specific increase will be observed in the 60–79 age range. Today, 20% of people aged 70–79 are diabetics. The aging of the world population is one of the most important causes of the increase in diabetes prevalence because increasing age is a significant risk factor in the development of diabetes. A greater number of patients with type 2 diabetes (>90%) are seen in the elderly population. Both the insulin resistance and beta cell dysfunction play a crucial role in its pathogenesis. Insulin resistance due to advanced age is related to adiposity, sarcopenia, and physical inactivity. In addition, LADA presented at advanced age and type 1 diabetics diagnosed at an early age reaching to old age are also diabetics in the elderly. Other concomitant diseases and conditions caused by aging along with diabetes become more frequent with increasing life expectancy. Kidney failure, heart failure, ischemic heart disease stroke, urinary incontinence, cognitive disorder, dementia, sarcopenia, and osteoporosis are...
the main causes of diabetes management in the elderly. Therefore, a treatment approach should be considered in elderly diabetics also taking into account other comorbid conditions. In the light of all these developments, diabetes treatment has become the target of cardiovascular protection in addition to reducing blood sugar.

**Physiopathological Changes In Elderly Diabetics**

Although there is no evidence that the pathophysiology of elderly with type 2 diabetes is different from that of young people, the beta cell defect, which is accelerated by insulin resistance in advanced age, is more prominent. Therefore, postprandial hyperglycemia is more evident.

Nighttime hyperglycemia is not clear because the nocturnal peak of cortisol is weak in the elderly. There is a delay in the glucose absorption and a delay in hepatic glucose production suppression. LBM is associated with an increase in insulin resistance due to the decrease in body fat and increase in LBM.

**Changes in the Signs and Symptoms of Diabetes in the Elderly**

Physiological changes that take place with aging may alter the signs and symptoms of classical diabetes. Hyperglycemia symptoms may vary. Glucosuria may not be present because the renal glucosuria threshold increases with age. Polydipsia may not be present because of changes in the perception of thirst. Frequently, dry eye, dry mouth, confusion, urinary incontinence, or diabetes complications may be the first signs and symptoms.

In the elderly, dehydration should be kept in mind as a result of insensitivity to hunger and sometimes insensitivity to the feeling of satiety.

**Nutrition Changes In Elderly Diabetics**

In elderly diabetics, mealtimes may vary or may not be predictable. Diabetics who use insulin may not adapt to the meals. The incidence of malnutrition in elderly people with diabetes is increased. This is due to morbidities (infections, end-stage renal failure, or cancer), anorexia due to drugs, or excessive restriction of the diet. Subclinical vitamins and essential nutrient deficiencies may play a role in the impairment of cognitive functions.

**Conditions From Age and Diagnosis Relations with Diseases**

With increasing age, there is a decrease in the functional capacity, whereas falls, dementia, urinary incontinence, polyfarkasia, resistant pain, and depression frequency increase.

**Inadequacy in functional capacity:** Diabetes increases the risk of not performing daily work 2–2.5 times. Difficulty in providing self-care, tremor, osteoarthritis, affective, and cognitive diseases require the help of someone else to make the diabetes treatment easier.

**Dementia:** The weight loss due to the insensitivity to the feeling of hunger in severe dementia and dehydration resulting from the insensitivity to satiety (if not corrected, nonketotic hyperosmolar state may occur) complicate diabetes management. Therefore, an annual screening is recommended in mild cognitive dysfunction and dementia diagnosis.

**Frailty:** In diabetic individuals, aging is faster, and in the presence of a large number of chronic diseases affecting multiple systems, frailty starts at an earlier age. A decrease in the muscle and nerve function, decreased cardiopulmonary reserve, difficult movement, weakness in one hand, fatigue, more than five diseases, weight loss ≥5% in 1 year or less have been determined. For this reason, sarcopenia should be evaluated in diabetics. Resistance exercises that increase the muscle strength should be recommended. Protein support should be given if necessary, and vitamin D and anabolic therapy are not recommended.

**Urinary incontinence:** The SGLT2 inhibitors should not be given to such diabetics. Drugs that may cause sarcopenia should be reviewed, and metformin should be carefully administered because it may reduce the appetite and facilitate weight loss.

**Depression:** In diabetic individuals, aging is faster, and in the presence of a large number of chronic diseases affecting multiple systems, frailty starts at an earlier age. A decrease in the muscle and nerve function, decreased cardiopulmonary reserve, difficult movement, weakness in one hand, fatigue, more than five diseases, weight loss ≥5% in 1 year or less have been determined. For this reason, sarcopenia should be evaluated in diabetics. Resistance exercises that increase the muscle strength should be recommended. Protein support should be given if necessary, and vitamin D and anabolic therapy are not recommended.

**Diabetes management.** Therefore, an annual screening is recommended in mild cognitive dysfunction and dementia diagnosis.

**Goals of Glycemia in Elderly Diabetics and Monitoring**

Different glycemia targets should be planned in older diabetics, considering the age, type of diabetes, duration, the frequency of hypoglycemia, comorbid conditions, and functional status. The most feared complication of hypoglycemia is the hypoglycemia-induced hospitalization exceeds hyperglycemia-induced hospitalization rates in elderly patients with diabetes.
normal and life expectancy long enough to benefit from treatment, A1c should be targeted to <7%, as in young people with diabetes.

In elderly diabetics who have multiple chronic diseases, mild to moderate cognitive impairment, and shortened life expectancy, A1c should target 7.1%–8%, fasting and pre-meal plasma glucose at 90–150 mg/dl, and overnight plasma glucose at 100–180 mg/dl.

Glycemic and metabolic targets should be kept more flexible in the elderly with advanced complications who have significant health problems, have a short life expectancy, are fragile, functional, or have a limited cognitive capacity. For these patients, A1C <8.5, fasting or pre-meal plasma glucose at 100–180 mg/dl and night plasma glucose at 110–200 mg/dl is recommended.[12]

**Nutritional Status and Treatment in Elderly Diabetics**

The energy requirement in the elderly is 20%–30% lower due to a different body composition and less frequent and sternus exercise. Aging is accompanied by many biological changes that may lead to nutritional deficiencies. These changes are related to taste, smell, and chewing, changes in the saliva flow, gastric acidity, changes in the hepatic and renal functions, multiple drug use, alcoholism, and difficulties in food preparation. The assessment should start with a nutritional history, including a psychosocial and environmental assessment.

**Exercise in Elderly Diabetics**

Physical activity, especially endurance exercises, is necessary to prevent muscle loss. Exercise prevents the decrease caused by aging in the maximal aerobic capacity and a decrease in atherosclerotic risk factors. A hundred and fifty minutes of moderate exercise (50% maximum heart rate) are recommended per week. If there are no contraindications, resistance exercises are recommended two times a week. Cardiac ischemia, musculoskeletal damage, the presence of neuropathy, and hypoglycemia (insulin or insulin secretagogue) should be considered.[12]

**Principles of Treatment in Elderly Diabetics**

There are no large randomized controlled trials that examined the control of diabetes and its effects on vascular complications in the elderly (>75 years). Larger reductions in morbidity and mortality occur by controlling other cardiovascular risk factors rather than glycemic control alone. It is necessary consider the age limit for the antidiabetic drugs to be used (Table 1). There is serious evidence for the control of hypertension. Despite the benefits of primary protection, there is little evidence for lipid lowering and aspirin.

The screening of diabetes complications should be individualized. Treatments of hypertension and lipid should be individualized in addition to diabetes. Treatment of lipid and aspirin provides primary and secondary protection. Influenza and conjugated pneumococcal vaccination also should not be forgotten.

Heart failure is a condition that should not be ignored in the treatment of diabetes. In recent years, drugs that reduce or increase the risk of heart failure have become important in the treatment of diabetes (Table 2).

The risk of fractures in the treatment of diabetes in the elderly should also be considered (Table 3).

The incidence of sarcopenia is high in the elderly. Sulfonylureas that may lead to sarcopenia should be considered (Table 4).

**Metformin**

Metformin is an indispensable first-line drug in the elderly as well. Its efficiency and tolerability are good. The risk of hypoglycemia is low, and its effect on weight is neutral or it leads to weight loss. Long-term randomized controlled tri-

| Table 1. Safe age limits for antidiabetic drugs application in the elderly |
| --- |
| **Age and the treatment of antidiabetics** |
| Metformin | Not recommended for use after 80 years of age |
| Sulphonylureas, glinides | No age restrictions |
| Pioglitazones | Up to 75 years old |
| Sitagliptin, saxagliptin | Safe for 65–75 years |
| Vildagliptin | Safe for 75–84 years |
| GLP-1 A | Up to 75 years old |
| SGLT2 inhibitors | Up to 75 years old |

| Table 2. Correlation between heart failure and antidiabetic drugs |
| --- |
| **Antidiabetics and heart failure** |
| DECREASE OF RISK | SGLT2 inhibitors (empagliflozin and canagliflozin) |
| Glitazon (RECORD, PROactive) |
| GLP-1 agonist (LEADER study) NS | Saxagliptin (SAVOR–TIMI53) |

| Table 3. Relationship between the fracture risk and antidiabetics |
| --- |
| **Fracture risk and OAD** |
| INCREASE IN FRACTURE RISK | Sulphonylureas |
| DPP-IV Inhibitors |
| TZD |
| SGLT2 Inhibitors |
als, such as the UKPDS, have demonstrated that metformin has beneficial effects on specific complications of diabetes and on mortality and morbidity.

It has been suggested that metformin can protect the epigenetic modifying enzymes, such as histone acetyl transferase and histone methyl transferase via AMP-kinase enzyme, and thus protect against cancer, cardiovascular diseases, a decrease in cognitive functions, and provide anti-aging effects.\[13\] The effects on heart failure and atherosclerotic cardiovascular disease and diabetic renal disease progression are neutral. Renal dysfunction eGFR is 30–45 ml/min in half dose) and eGFR is contraindicated in <30 ml/min. Nonobese patients with diabetes should be treated with low doses of metformin. In imaging procedures, metformin should be discontinued 2 days in advance. Metformin should be used in low doses or applied in an extended release form to reduce gastrointestinal side effects.

**Sulphonylureas**

They are powerful and fast-acting but have side effects, such as hypoglycemia and weight gain. Therefore, short effects, such as glipizide or slow release forms, should be preferred in the elderly. Due to the slow release forms, the risk of hypoglycemia is less than that of the old formulations. The risks of hypoglycemia are the age >75 years old, renal failure, heart failure, and dementia. The effects on heart failure and atherosclerotic cardiovascular disease are neutral. The effect on diabetic renal disease progression is neutral. In the ADVANCE study performed with the glyburide MR form, a decrease of 21% was observed on microalbuminuria.\[14\] In the UKPDS study, microvascular risk reduction was demonstrated.\[16\]

**Non Sulfonylusion Secretagog Glinides**

The effect starts quickly and ends fast. It is more expressed on postprandial blood glucose. These properties are preferred in postprandial hyperglycemia. Its use is very limited, and its combination with other drugs is inevitable. Particularly preferred is the combination with metformin and/or basal insulin, which has effect on fasting blood glucose. However, hypoglycemia and weight gain are the most undesirable for the elderly. In addition, taking the drug before each main meal is an advantage in terms of flexible use in those who have a habit of eating irregularly, but the need to use it three times a day is a disadvantage that reduces drug compliance. The effects on heart failure, atherosclerotic heart disease, and diabetic nephropathy are neutral. Because 90% of the repaglinide is excreted with bile, it can be easily used in renal failure. Nateglinide is contraindicated in renal insufficiency because of the 80% renal excretion. Glinides may not be effective in patients with prolonged diabetes, such as sulphonylureas.\[17, 18\]

**Glitazones**

Glitazones, which are nuclear receptors and PPAR agonists, are the lowest antidiabetic agents with a hypoglycemic effect. Large randomized prospective cardiovascular outcome studies have shown strong evidence that pioglitazone may delay the atherosclerotic process (PERISCOPE and CHICAGO studies)\[19, 20\] and reduce cardiovascular events (IRIS and PROactive studies),\[21, 22\] but its use is limited in the elderly. The most important reasons for this are edema, heart failure risk, increased fracture risk, and weight gain. Initial concerns about the increase of bladder cancer have decreased. In spite of these, it can be used with low doses in the early elderly group because of its benefits in secondary prevention of macrovascular diseases, such as myocardial infraction (MI) or stroke.\[23–26\]

**DPP-IV Inhibitors**

DPP-IV inhibitors reduce HbA1c by 0.6%–1%. The DPP-4 inhibitor can be preferred in the elderly because of the low side effect of hypoglycemia and no weight gain. Also, it can be preferred in the elderly who have the habit of eating irregularly, that is, who neglect or forget to eat. It has been shown that the risk of heart failure increases with saxagliptin and alogliptin.\[27\] The dose should be adjusted in the renal failure except for linagliptin. If GFR >50 ml/min, it should be continued with 100 mg sitagliptin, 50 mg sitagliptin for GFR 30–50 ml/min, 25 mg sitagliptin for GFR <30 ml/min, and in hemodialysis/peritoneal dialysis (because it is excreted unchanged in the urine). Saxagliptin 2.5 mg is used safely and effectively in moderate-to-severe renal failure. Vildagliptin at a dose of 50 mg can be used in moderate and severe renal failure, without the need for dose change in mild CRF.

**GLP-1 R Agonists**

The GLP-1 R agonists reduce HbA1c by 1.0%–2%. The weight loss effect and low hypoglycemic side effects are

---

**Table 4. Relationship between sarcopenia and antidiabetics**

| Sarcopenia and the treatment of antidiabetics | *Sarcopenia and the treatment of antidiabetics* |
| Metformin | Its effect is controversial/partially useful |
| TZD | Effective in animal models |
| Sulphonylureas, glinides | Triggers muscle atrophy |
| Incretins | The effect on sarcopenia is useful |
| SGLT2 inhibitors | No data |
| Insulin | No corrective effect on muscle atrophy in elderly |
both advantages and disadvantages for the elderly. The effect on heart failure is neutral. As shown in the LEADER study, there was a decrease in nonfatal MI or nonfatal stroke in the presence of cardiovascular disease with liraglutide.\(^{28}\)

Also, in semaglutide and in type 2 diabetes, cardiovascular death was shown to decrease in nonfatal MI or nonfatal stroke.\(^{29}\) Liraglutidine has also been shown to have positive effects on the progression of diabetic renal disease. It has been reported to be effective and tolerable in the study performed with weekly exenatide in the elderly.\(^{30}\) Despite all these positive effects, it should be used with caution in the elderly due to its weight-loss effect and gastrointestinal side effects.\(^{31}\)

### SGLT2 Inhibitors

SGLT2 inhibitors reduce HbA1c by 0.5%–1.0%. It is a suitable option in the elderly because of low hypoglycemic side effects, the weight-loss effect, and beneficial effects in heart failure, but the risk of genitourinary infection, dehydration, and fracture should not be ignored. Beneficial effects of canagliflozin and empagliflozin on heart failure, atherosclerotic cardiovascular disease, and diabetic renal disease progression were demonstrated, but the risk of amputation at the foot metatarsal and foot fingers was found to be high with canagliflozin.\(^{32–34}\) In patients with diabetes over 65 and over 75 years of age, the efficacy of dapagliflozin in the treatment lasting for 2 years was found to be higher than in the younger group.\(^{35}\) Because there is a GLP-1 receptor in the glomeruli, a diuretic effect can occur, so attention must be paid to the use of ACEI. SGLT2 inhibitors and furosemide diuretics should be used with caution because of an increase in creatinin. The risk of fracture increased was shown in canagliflozin, but not in empagliflozin and dapagliflozin (Table 5).

**Insulin Treatment**

When the first diagnosis of diabetes is made in the elderly, the diagnosis of Type 1 diabetes should be excluded. If the C-peptide level is found to be low in patients with low-diabetes, the C-peptide level is found to be low. If LADA or Type 1 diabetes is diagnosed, intensive insulin therapy should be performed. The most important point in the treatment of insulin in elderly diabetics is to give the patient the ability to monitor insulin. In patients who use insulin, not only HbA1c monitoring, but also the patient’s own glucose monitoring should be considered.

Patients with diabetes and hypoglycemia education should be given importance. Excessive insulin dose should be avoided by follow-up. Overdose insulin is not desirable because of both hypoglycemia and weight gain. Insulin treatment should be individualized, and the infrequent injection regimens should be used. In case of failure with OAD, basal insulin should be added to the current treatment and, if necessary, a basal + plus regimen should be planned by adding bolus insulin 1 or 2 or 3 times per day to meals. Again, premixed insulin regimen 1 or 2 or 3 times per day may be a good option.

**Oral Antidiabetic Drug use in Elderly Diabetics with Neurological Disease**

The incidence of hypoglycemia is directly related to dementia. In addition, hypoglycemia is a triggering factor for Alzheimer’s disease by causing hypocampal atrophy. It has been suggested that sulfonylureas increase the risk of Parkinson’s disease, whereas metformin decreases it. Pioglitazone has been reported to be protective against to Parkinson’s disease.\(^{36–38}\)

### Conclusion

Although the diabetes treatment approach does not differ in healthy elderly individuals, hypoglycemia is one of the most feared conditions, especially in the elderly. Therefore, metformin, DPP-IV inhibitors, and SGLT2 inhibitors should be considered first, with less risk of hypoglycemia. Low-dose sulfonylureas may also be used in selected cases. Insulin treatment should be individualized and the most rare injection regimens should be used. In case of failure with OAD, basal insulin should be added to the current treatment and, if necessary, a basal + plus regimen should be planned by adding bolus insulin 1 or 2 or 3 times per day to meals. The use of new antidiabetic drugs, such as GLP-1 analogues and SGLT2 inhibitors, has strengthened our ability to cope with the risk of hypoglycemia and cardiovascular events, which are the two most important drawbacks in the treatment of elderly people with diabetes. In elderly diabetics, inadequate treatment or excessive treatment and individualizing the treatment should be the most appropriate approach.

---

**Table 5. Risk of fracture in SGLT2 inhibitors**

| Risk of fracture and SGLT2 inhibitors | Canagliflozin | Empagliflozin and Dapagliflozin |
|---------------------------------------|--------------|----------------------------------|
| • Decrease in BMD                     |              | • Increased risk of fracture      |
| • Increase in fracture (4% vs. 2.6%)  |              | not shown                        |
| In those with a history of CV, in those with low GFR, the risk of high-dose diuretics increases (CANVAS study) | | |
| • Meta-analysis showed no significant increase in the fracture risk (OR 1.15, 95% CI 0.71–1.88) | | |

---

\(^{28}\) The Medical Bulletin of Sisli Etfal Hospital
Disclosures

Peer-review: Externally peer-reviewed.
Conflict of Interest: None declared.

References

1. Chen LK, Chen YM, Lin MH, Peng LN, Hwang SJ. Care of elderly patients with diabetes mellitus: a focus on frailty. Ageing Res Rev 2010;9 Suppl 1:S18–22.
2. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care 2012;35:2650–64.
3. Abbatecola AM, Paolisso G. Diabetes care targets in older persons. Diabetes Res Clin Pract 2009;86 Suppl 1:S35–40.
4. Turnbull PJ, Sinclair AJ. Evaluation of nutritional status and its relationship with functional status in older citizens with diabetes mellitus using the mini nutritional assessment (MNA) tool--a preliminary investigation. J Nutr Health Aging 2002;6:185–9.
5. Morley JE. Diabetes, sarcopenia, and frailty. Clin Geriatr Med 2008;24:455–69.
6. Rockwood K. Frailty and its definition: a worthy challenge. J Am Geriatr Soc 2005;53:1069–70.
7. Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik JM, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging 2018;22:1148–61.
8. Brown JS, Vittinghoff E, Lin F, Nyberg LM, Kusek JW, Kanaya AM. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002. Diabetes Care 2006;29:1307–12.
9. Maraldi C, Volpato S, Penninx BW, Yaffe K, Simonsick EM, Strotmeyer ES, et al. Diabetes mellitus, glycemic control, and incident depressive symptoms among 70- to 79-year-old persons: the health, aging, and body composition study. Arch Intern Med 2007;167:1137–44.
10. Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med 2014;174:1116–24.
11. Jennings PE. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus. Drugs Aging 1997;10:323–31.
12. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Derneği (TEMED). Yaşllarla diyabet. In: Diabetes mellitus ve komplikasyonların tani, tedavi ve izlem kilavuzu 2018. Ankara: TEMED. p. 205.
13. Bridgeman SC, Ellison GC, Melton PE, Newsholme P, Mamotte CDS. Epigenetic effects of metformin: From molecular mechanisms to clinical implications. Diabetes Obes Metab 2018;20:1553–62.
14. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.
15. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care 2016;39:694–700.
16. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53.
17. Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, et al. Improvement of insulin sensitivity and beta-cell function by metformin and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007;9:558–65.
18. Harsch IA, Kaestner RH, Konturek PC. Hypoglycemic side effects of sulfonylureas and repaglinide in ageing persons - knowledge and self-management. J Physiol Pharmacol 2018;69:647–50.
19. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kuper S, Perez A, et al; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561–73.
20. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572–81.
21. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al; IRIS Trial Investigators. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016;374:1321–31.
22. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–89.
23. Rajagopal R, Perez A, Ye Z, Khan M, Murray FT. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drugs Aging 2004;21:259–71.
24. Graham DJ, Ouellet-Hellstrom R, MacCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411–8.
25. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events04). Stroke 2007;38:865–73.
26. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–26.
27. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF,
Nauck MA, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311–22.

29. Marso SP, Bain SC, Consoli A, Eliashewitz FG, Jódar E, Leiter LA, et al; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834–44.

30. Loughlin AM, Qiao Q, Nunes AP, Öhman P, Ezzy S, Yochum L, et al. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States. Diabetes Obes Metab 2018;20:898–909.

31. Pawaskar M, Li Q, Reynolds MW. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting. Curr Med Res Opin 2012;28:991–7.

32. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644–57.

33. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016;375:323–34.

34. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117–28.

35. Fioretto P, Mansfield TA, Ptaszynska A, Yavin Y, Johnsson E, Parikh S. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. Drugs Aging 2016;33:511–22.

36. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord 2012;18:753–8.

37. Rotermund C, Machetanz G, Fitzgerald JC. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2018;9:400.

38. Brakedal B, Flønes I, Reiter SF, Torkildsen Ø, Dölle C, Assmus J, et al. Glitazone use associated with reduced risk of Parkinson's disease. Mov Disord 2017;32:1594–9.